Bulletin
Investor Alert

press release

Aug. 12, 2021, 8:01 a.m. EDT

Kintara Therapeutics to Present at the Investor Summit Virtual Conference on August 17, 2021

SAN DIEGO, Aug. 12, 2021 /PRNewswire/ --  Kintara Therapeutics, Inc . /zigman2/quotes/209332458/composite KTRA -0.49% , a biopharmaceutical company developing novel cancer therapies for patients who are failing or are resistant to current treatment regimens, announced today that its Chief Executive Officer, Saiid Zarrabian, will present at the Investor Summit Conference being held August 17 – 18, 2021.

Mr. Zarrabian will deliver his corporate presentation on August 17, 2021 at 12:30 p.m.ET.

Investors can also request a one-on-one meeting with Mr. Zarrabian to be arranged following the conclusion of the conference.

Investors can register here: Q3 Investor Summit Investor Registration

About Kintara

Located in San Diego, California, Kintara /zigman2/quotes/209332458/composite KTRA -0.49% is dedicated to the development of novel cancer therapies for patients with rare unmet medical needs. Kintara is currently developing two Phase 3-ready therapeutics, VAL-083 for glioblastoma multiforme (GBM) and REM-001 for cutaneous metastatic breast cancer (CMBC).

VAL-083 is a "first-in-class", small-molecule, bifunctional alkylating agent that crosses the blood-brain-barrier and has a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian and other solid tumors (e.g., NSCLC, bladder cancer, head and neck) in U.S. clinical trials sponsored by the National Cancer Institute (NCI). Based on Kintara's internal research programs and these prior NCI-sponsored clinical studies, Kintara is currently conducting clinical trials to support the development and commercialization of VAL-083 in GBM.

REM-001 is a proprietary, late-stage photodynamic therapy platform that holds promise as a localized cutaneous, or visceral, tumor treatment as well as in other potential indications. REM-001 therapy has been previously studied in four Phase 2/3 clinical trials in patients with CMBC who had previously received chemotherapy and/or failed radiation therapy. With clinical efficacy of 80% complete responses of CMBC evaluable lesions and an existing robust safety database of approximately 1,100 patients across multiple indications, Kintara is advancing the REM-001 CMBC program to late-stage pivotal testing. 

For more information, please visit  www.kintara.com  or follow us on Twitter at  @Kintara_TheraFacebook  and  Linkedin .

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the status of the Company's clinical trials and the GBM AGILE study. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the impact of the COVID-19 pandemic on the Company's operations and clinical trials; the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended June 30, 2020, the Company's Quarterly Reports on Form 10-Q, and the Company's Current Reports on Form 8-K.

CONTACTS Investors
CORE IR
516-222-2560
ir@coreir.com

Media
Jules Abraham
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com

 

Cision
View original content to download multimedia: https://www.prnewswire.com/news-releases/kintara-therapeutics-to-present-at-the-investor-summit-virtual-conference-on-august-17-2021-301354010.html

SOURCE Kintara Therapeutics

COMTEX_391445510/2454/2021-08-12T08:00:57

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

Copyright (C) 2021 PR Newswire. All rights reserved

/zigman2/quotes/209332458/composite
US : U.S.: Nasdaq
$ 0.16
-0.0008 -0.49%
Volume: 1.63M
May 17, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$10.66 million
Rev. per Employee
N/A
loading...
/zigman2/quotes/209332458/composite
US : U.S.: Nasdaq
$ 0.16
-0.0008 -0.49%
Volume: 1.63M
May 17, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$10.66 million
Rev. per Employee
N/A
loading...

Comtex

Partner Center

Link to MarketWatch's Slice.